May 2, 2024

Ren Russo, Pharm.D. President and Chief Executive Officer Xilio Therapeutics, Inc. 828 Winter Street, Suite 300 Waltham, Massachusetts 02451 Re: Xilio Therapeutics, Inc. Registration Statement on Form S-3 Filed April 30, 2024 File No. 333-279015 Dear Ren Russo: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely,

Division of Corporation Finance Office of Life Sciences cc: Molly W. Fox, Esq.